- Conditions
- Myelodysplastic Syndrome
- Interventions
- ON 01910.Na
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 28,800
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arthropathy of Knee Joint, Arthropathy of Hip Joint
- Interventions
- personalized prehabilitation
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
- Interventions
- SPI-62, Placebo
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
- Conditions
- Lung Cancer
- Interventions
- Digital-based support, Traditional-based support + Nicotine replacement therapy (NRT)
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Heart Failure, Cognitive Impairment
- Interventions
- Mindfulness Training + Enhanced Usual Care, Enhanced Usual Care
- Behavioral · Other
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Atherosclerosis
- Interventions
- Darapladib, Diltiazem
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Substance Dependence
- Interventions
- varenicline, placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Emeryville, California
- Conditions
- Dementia
- Interventions
- Cholinesterase inhibitor, Sham discontinuation
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Boise, Idaho • Bedford, Massachusetts + 1 more
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia
- Interventions
- Azacitidine, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
- Drug · Other · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hypertension, Mild Cognitive Impairment
- Interventions
- Mindfulness and DASH Diet Education, Education group
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Preterm Birth, Pregnancy, Multifetal
- Interventions
- 17 alpha-hydroxyprogesterone caproate (17P)
- Drug
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 795 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
- Conditions
- Gout
- Interventions
- Febuxostat XR
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Palliative Care
- Interventions
- Acupuncture
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PreDiabetes
- Interventions
- Lifestyle Interventions
- Behavioral
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 21 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Acoma Pueblo, New Mexico
- Conditions
- Healthy
- Interventions
- PF614, Oxycodone extended-release, Naltrexone Hydrochloride
- Drug
- Lead sponsor
- Ensysce Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Healthy
- Interventions
- Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
- Biological
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
- Conditions
- Immunosuppression
- Interventions
- Blood Sample
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Opioid Use, Fractures, Bone, Trauma
- Interventions
- Narcotic pain medication, Nonnarcotic pain medications
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Healthy
- Interventions
- Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Nicotine Dependence
- Interventions
- nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Solid Malignancy, Solid Tumor
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
- Interventions
- ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
- Drug · Other
- Lead sponsor
- Oramed, Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tustin, California
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
- Interventions
- TTI-101
- Drug
- Lead sponsor
- Tvardi Therapeutics, Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Houston, Texas • San Antonio, Texas
- Conditions
- Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation, Vascular Anomaly, Dercum Disease
- Interventions
- NIRFLI with ICG
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 3 Months and older
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2030
- U.S. locations
- 3
- States / cities
- Houston, Texas • The Woodlands, Texas